Business
Additional Listing
Additional Listing.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 3736Q Immupharma PLC 14 October 2013 \n\n\n\n\n\nFOR IMMEDIATE RELEASE\n\n\n 14 OCTOBER 2013\n\n\n\n\n \n \nImmuPharma plc\n \n \nADDITIONAL LISTING AND TOTAL VOTING RIGHTS\n \n \nImmuPharma plc (LSE:IMM) (\"Immupharma\" or the \"Company\"), the specialist discovery and development pharmaceutical company announces that following the exercise of warrants held by the Darwin Strategic Limited (\"Darwin\"), application has been made to the London Stock Exchange for the admission of 750,000 new ordinary shares of 10 pence each in the Company to trading on AIM. It is expected that these new ordinary shares, which will rank pari passu with the existing ordinary shares of the Company, will be admitted to trading on 15 October 2013.\n \nFollowing the allotment of the new ordinary shares, the Company's issued share capital will consist of 82,282,463 Ordinary Shares of 10p each which entitle the holder to one vote per share. Therefore, the total number of voting rights is 82,282,463. \n \nThe above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules. \n \nThe warrants that Darwin exercised were issued at the same time as ImmuPharma and Darwin entered into an Equity Finance Facility (\"EFF\") agreement in May 2013. The EFF agreement provides ImmuPharma with a facility of up to £50 million which (subject to certain limited restrictions) can be drawn down at any time over the next five years. ImmuPharma is under no obligation to make a draw down and has not initiated any draw downs of this facility to date.\n \n \n \nFor further information please contact:\n\n\n\n\nImmuPharma plc\n\n\n+ 44 (0) 20 7152 4080\n\n\n\n\nDimitri Dimitriou, Chief Executive Officer\n\n\n\n\n\n\n\nDr Robert Zimmer, President and Chief Scientific Officer\n\n\n\n\n\n\n\nRichard Warr, Chairman\n\n\n\n\n\n\n\nTracy Weimar, Vice President, Operations and Finance\n\n\n\n\n\n\n\nLisa Baderoon, Head of Investor Relations\n\n\n+ 44 (0) 7721 413496\n\n\n\n\n\n\n\n\n\n\n\n\nPanmure, Gordon & Co., NOMAD & Broker\n\n\n+44 (0) 20 7886 2500\n\n\n\n\nHugh Morgan, Fr...